Orion Oyj: Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer

ORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive

Related Keywords

Germany ,Japan ,United States ,United Kingdom ,China ,Italy ,Helsinki ,Eteläuomen Läi ,Finland ,France ,Spain ,Finnish ,Tuukka Hirvonen ,Clin Onc ,European Union ,European Medicines Agency ,European Commission ,Committee For Medicinal Products Human Use ,Orion Corporation ,Medicinal Products ,Human Use ,New England Journal ,Cancer Atlas ,Hormone Sensitive Prostate Cancer ,Treatment Strategies ,Oncol Ther ,Cancer Incidence ,Mortal Wkly Rep ,Castration Sensitive Prostate Cancer ,Optimizing Patient Selection ,Englj Med ,Cancer Statistics ,Mortality Worldwide ,Cancer Journal ,Accessed December ,Orion ,Positive ,Thmp ,Opinion ,Darolutamide ,Combination ,Udocetaxel ,Treatment ,Metastatic ,Ormone ,Ensitive ,Prostate ,Dancer ,